Literature DB >> 8907316

A racial difference in the prevalence of the Arg506-->Gln mutation.

W C Hooper1, A Dilley, M J Ribeiro, J Benson, H Austin, V Silva, P Rawlins, N K Wenger, B L Evatt.   

Abstract

Several recent studies have reported that the factor V Arg506-->Gln mutation is present in 3-10% of adults of European descent. To determine if the prevalence is comparable among Blacks, we have initiated a case-control study in a large urban hospital in Atlanta which serves a substantial black population. We have evaluated 131 black subjects with confirmed venous or arterial thrombosis and 61 black subjects without a history of thrombosis. Only one case and one control were positive for the Arg506-->Gln mutation. We conclude that the mutation is more common among Whites than Blacks.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8907316     DOI: 10.1016/0049-3848(96)00032-1

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  5 in total

1.  Racial differences in the prevalence of Factor V Leiden mutation among patients on chronic warfarin therapy.

Authors:  N A Limdi; T M Beasley; D B Allison; C A Rivers; R T Acton
Journal:  Blood Cells Mol Dis       Date:  2006-08-02       Impact factor: 3.039

2.  Prevalence of positive factor V Leiden and prothrombin mutations in samples tested for thrombophilia in Saudi Arabia.

Authors:  Fatimah Madkhaly; Abdulaziz Alshaikh; Hala Aba Alkhail; Randa Alnounou; Tarek Owaidah
Journal:  Am J Blood Res       Date:  2021-06-15

Review 3.  Physiology, genetics, and cardiovascular disease: focus on African Americans.

Authors:  Gary H Gibbons
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-04       Impact factor: 3.738

Review 4.  The relationship between FV Leiden and pulmonary embolism.

Authors:  W Craig Hooper; Christine De Staercke
Journal:  Respir Res       Date:  2001-11-19

5.  Sickle cell trait: is there an increased VTE risk in pregnancy and the postpartum?

Authors:  Sofya Pintova; Hillel W Cohen; Henny H Billett
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.